Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Nuvation Bio Inc.NYSE: NUVB

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation turns negative

Q2 FY2026 stock-based compensation was -$9.03M, compared with $12.03M a year earlier. Trailing-twelve-month stock-based compensation was -$19.89M. Over 3 fiscal years it compounded at +30.1% a year.

Context

  • Stock-based compensation amounted to 57.1% of revenue in FY2025, down 352.9 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly stock-based compensation holds near -$9.03M or moves back toward the trailing-twelve-month quarterly average of -$4.97M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$9.03M-200.0% QoQ
Last fiscal yearDec 2025
$35.89M+11.2% YoY
LTMJun 2026
-$19.89M-153.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-175.1%——
1 year+11.2%——
3-year CAGR+30.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
35.89M USD
Year-over-year change
+11.2%
4-year CAGR
+40.3%

Stock-Based Compensation vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 stock-based compensation of $19.89M is the 8th largest of the 11 companies compared; the peer median is $43.55M.
  • Its year-over-year change of -153.0% is the lowest of 11, against a peer median of +0.5%.
  • Stock-based compensation amounts to 11.7% of revenue for NUVB, versus a peer median of 92.8%.
NUVB Competitors Peer median
Stock-Based Compensation for NUVB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VRDNViridian Therapeutics, Inc.LTM Jun 2026$53.61M +38.3%+30.9%75.4%
GPCRStructure Therapeutics Inc.LTM Jun 2026$51.48M +103.6%+125.9%—
VERAVera Therapeutics, Inc.LTM Jun 2026$49.78M +71.5%+62.2%—
ABCLAbCellera Biologics Inc.LTM Sep 2026$48.87M -15.9%+4.1%72.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M +35.8%+36.5%92.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026$38.79M +1.8%+32.7%179.5%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$36.81M -0.7%—32869.6%
NUVBNuvation Bio Inc.LTM Jun 2026$19.89M -153.0%+30.1%11.7%
QUREuniQure N.V.LTM Mar 2026$18.36M -5.7%-19.7%101.5%
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$7.89M -59.1%-23.1%2.5%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.76M -94.6%+47.1%—
Peer median (excluding NUVB) $43.55M+0.5%+32.7%92.8%

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Depreciation & Amortization184K199K222K683K1.74M
Deferred Income Tax00000
Stock-Based Compensation9.27M16.29M19.51M32.28M35.89M
Change in Working Capital4.79M(3.45M)540K(12.51M)(11.98M)
Accounts Receivables(1.95M)554K(1.22M)(12.59M)(3.07M)
Inventory0000(11.41M)
Accounts Payables1.86M(1.79M)70K(1.65M)3.13M
Other Working Capital4.88M(2.22M)1.69M1.74M(630K)
Other Non-Cash Items4.41M(4.95M)(12.47M)417.08M5.55M
Operating Cash Flow(68.19M)(96.11M)(68M)(130.41M)(173.43M)
Capital Expenditures(282K)(370K)(69K)(162K)(354K)
Acquisitions (Net)00012.43M0
Purchases of Investments(609.3M)(520.31M)(703.37M)(339.65M)(354.42M)
Sales of Investments154.91M584.12M712.35M450.08M462.29M
Other Investing Activities013K14K00
Investing Cash Flow(454.67M)63.46M8.92M122.7M99.52M
Debt Repayment000(4.55M)191.11M
Common Stock Issued0004.89M11.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities625.53M1.33M628K00
Financing Cash Flow625.53M1.33M628K331K202.54M
Effect of Forex Changes000453K(265K)
Net Change in Cash102.67M(31.32M)(58.45M)(6.93M)128.36M
Free Cash Flow(68.47M)(96.48M)(68.07M)(130.58M)(173.78M)

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.